Dana Chase

Aug 30, 2024 | onclive.com | Dana Chase

Dana M. Chase, MD, associate professor, obstetrics and gynecology, Division of Gynecologic Oncology, the University of California, Los Angeles, discusses the significance of the FDA approval of dostarlimab-gxly (Jemperli) plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Apr 25, 2024 | touchoncology.com | Chelsea Stewart |Dana Chase

The treatment of advanced or recurrent endometrial cancer has advanced significantly in recent years. This is particularly important, given the rising mortality rates of endometrial cancer, particularly among high-risk subtypes.1 Platinum-based chemotherapy had long been the standard of care in patients with advanced or recurrent endometrial cancer. New approaches to the classification of endometrial cancer based on the molecular profile have allowed for a more targeted approach to treatment.

Nov 3, 2023 | redjournal.org | Dana Chase

The standard of care for recurrence of metastatic endometrial cancer is systemic therapy.This treatment could include traditional cytotoxic chemotherapy; however, the biomarker profile of the patient now directs the choice of agent.

Apr 24, 2023 | cancernetwork.com | Ritu Salani |Dana Chase

In a Twitter Spaces edition of the Oncology On-The-Go podcast, Ritu Salani, MD, and Dana Chase, MD, spoke with CancerNetwork® about findings presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, and how they may impact clinical practice.